Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.11
€0.04(1.75%)
At close: 4:00 PM EDT
€2.11
€0.04(1.75%)
Day’s Range― - ―
52-Week Range€2.03 - €5.42
Previous CloseN/A
Volume117.56K
Average Volume (3M)1.29M
Market Cap
€407.36M
Enterprise Value€589.53
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€152.15M
Bulls Say, Bears Say
Bulls Say
Unique Lyme Vaccine OpportunityValneva’s VLA15 represents a rare, first-mover commercial opportunity in Lyme vaccination with broad serotype coverage for North America and Europe and clear unmet medical need. A successful approval/launch would establish durable market exclusivity, sizable addressable populations and strong pricing leverage over years.
Manufacturing Network Expansion And Non‑US ApprovalsCompletion of manufacturing transfers and non‑US regulatory approvals strengthens Valneva’s supply footprint and reduces reliance on single sites. Local partnerships and endemic‑country manufacturing improve access, lower logistics risk, and support scalable commercial rollouts for vaccines in large public‑health programs.
Restructuring To Materially Cut Operating ExpensesA planned 25–35% reduction in operating expenses is a structural step to improve cash flow sustainability and operating leverage. If achieved, this reduces future financing reliance, extends runway for pipeline readouts and makes revenue improvements translate more directly into durable margin recovery.
Bears Say
Weak Cash Generation And Elevated LeveragePersistently negative operating and free cash flows combined with elevated debt and a shrinking equity base materially raise refinancing and dilution risk. Limited internal cash generation undermines funding for late‑stage programs and increases dependence on external capital or asset sales over the medium term.
Declining Revenues And Compressing Gross MarginsSharp revenue contraction and large gross‑margin deterioration indicate fragile demand and structural cost issues (idle costs, failed batches, onerous contracts). Margin weakness reduces cash generation potential even if sales recover, making durable profitability contingent on operational fixes and steadier product demand.
Regulatory/manufacturing Constraint On U.S. SupplyFDA observations that limit Almeida’s use for U.S. supply create a structural operational risk: ongoing higher manufacturing costs, potential supply interruptions, and the need for additional remediation or alternate capacity. Such constraints can delay market access and raise long‑term cost of goods.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.03 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €407.36M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went up 1.897%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE (VLA) is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, with an emphasis on products addressing unmet medical needs. It operates in the biotechnology/pharmaceuticals sector and markets travel and endemic-disease vaccines, while also advancing a pipeline of vaccine candidates through clinical development and pursuing collaborations with public and private partners.